Vaccination and Immunization

Moderna has announced that their latest BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, has been granted Emergency Use Authorization by the US Food and Drug Administration.

In this article, declining trends in vaccination across the United States are discussed, along with how providers can reduce vaccine hesitancy.

Study links discrepancy to adults’ misbeliefs about vaccine safety.

Pfizer and BioNTech have applied to the FDA for Emergency Use Authorization of their Omicron BA.4/BA.5-adapted bivalent vaccine booster for use in pediatric patients aged 3 to 11 years.

In a recent report, the American Academy of Pediatrics discussed how influenza affects children and how it can be prevented.

In a recent study, participants who had received a COVID-19 vaccine saw an average increase in menstrual cycle length of less than 1 day.

In a new statement, the American Academy of Pediatrics outlines the importance of immunization information systems.

In 2 new education documents, Physicians for Informed Consent outlines the risks of Hepatitis B compared to the risks of the Hepatitis B vaccination.

Infants of fully vaccinated mothers had fewer cases of hospitalization from COVID-19 than those unvaccinated.

Move comes after FDA give emergency use authorization for bivalent vaccines.

In a recent study, investigators found lower rates of COVID-19 infection and other adverse outcomes in vaccinated pregnant people over those unvaccinated.

Latest emergency use authorizations for Moderna, Pfizer-BioNTech vaccines.

Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen

Purchase follows FDA recommendation to include Omicron component in boosters.

Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.

Recently, the AAP announced the launch of a public health campaign to educate caregivers on the benefits of vaccinating all ages.

The FDA today approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.

The FDA today announces the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.

The US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee unanimously voted recently to recommend both the Pfizer-BioNTech and Moderna COVID-19 vaccines for individuals aged 6 months and older.

In a video for Contemporary Pediatrics®, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses an expansion of vaccine access likely to come with the FDA approval of the PRIORIX vaccine.

GSK plc today announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.

Pfizer-BioNTech reports strong immune response, high efficacy, and favorable safety in third dose of the COVID-19 vaccine.

Research suggests that COVID-19 vaccination may serve a therapeutic effect, possibly reducing the risk of developing long COVID when administered to those currently infected.

A look at what the Contemporary Pediatrics® team covered this week.

New data suggest pediatric patients with a history of cardiac arrest are highly susceptible to hospitalization if infected with SARS-CoV-2.

Nearly 9 million symptomatic cases also avoided.

Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.

A comparison of COVID-19 PCR tests and rapid self-tests found self-tests to be highly accurate and user-friendly for children.

Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.

Active immunization of pregnant women with investigational vaccine protected infants from RSV from birth through at least 6 months.